SIBO Clears in 63% of Cases With Rifaximin, But Recurrence Is the Real Problem

Small intestinal bacterial overgrowth is not a single disease with a single fix. Bacteria that belong in the colon take up residence in the small intestine, producing gases that cause bloating, diarrhea, and abdominal pain, and in severe cases, fueling liver damage and neurological decline. A comprehensive narrative review published in Medical Sciences by Maslennikov, Agarkova, Poluektova, Ulyanin, and colleagues synthesized 89 studies and six meta-analyses to map what actually works across six major disease categories. The picture that emerges is useful but humbling: the most popular treatment eliminates SIBO in roughly six out of ten people, placebo-controlled trial evidence is thin, and recurrence is nearly inevitable without maintenance strategies.

Rifaximin Eradicates SIBO in 63% of Cases, With Wide Variation by Disease

Rifaximin sits at the center of nearly every SIBO treatment protocol, and for understandable reasons. It is a non-absorbable antibiotic, meaning it stays in the gut and rarely causes the systemic side effects that make patients reluctant to repeat courses. The meta-analysis the review authors cite found rifaximin eliminated SIBO in 63% of cases overall, but that number masks enormous variation. In cirrhosis, eradication rates reached 90%. In functional bowel diseases and Parkinson's disease, the figure dropped to around 60%. The standard dose used across most studies was 1200 mg per day, and the review found that treatment duration between 3 and 28 days did not significantly change outcomes.

The troubling caveat: in small placebo-controlled randomized controlled trials focused on functional bowel diseases, rifaximin was not consistently superior to placebo for confirmed SIBO eradication. Uncontrolled studies in diarrhea-predominant irritable bowel syndrome showed eradication rates ranging from 29.3% to 87.5%, a spread wide enough to suggest that patient selection and diagnostic methodology account for as much variance as the drug itself. Adding partially hydrolyzed guar gum to rifaximin pushed eradication rates from 62.1% to 87.1% in IBS patients, a finding worth watching even if larger trials are needed to confirm it.

SIBO Recurrence Reaches 44% Within Nine Months of Successful Treatment

Eradicating SIBO once is only half the problem. The review reports recurrence rates of 12.6% at three months, 27.5% at six months, and 43.7% at nine months after successful rifaximin treatment. These figures align with the clinical reality that SIBO is frequently a symptom of an underlying structural or functional problem rather than a one-time infection. Common drivers include proton pump inhibitor use, bariatric surgeries, hypothyroidism, portal enteropathy, systemic sclerosis, lactase deficiency, and chronic pancreatitis. Treating SIBO without addressing the root cause is, in most cases, a temporary fix.

The condition is also far more widespread than many clinicians appreciate. SIBO is associated with hypothyroidism, inflammatory bowel disease, and diverticular disease, and its true prevalence across the general population remains difficult to pin down because diagnostic standards vary so widely between centers. Diagnosis currently relies on breath tests measuring hydrogen, methane, or both gases after carbohydrate ingestion, a method that is noninvasive and scalable but far from perfectly standardized. Small bowel aspirate culture is considered the gold-standard diagnostic method for SIBO, but it is invasive enough that breath testing remains the practical default, even though varying cut-off values between labs complicate cross-study comparisons.

One maintenance strategy stands out in the data. Minocycline combined with Bacillus coagulans spores and fructo-oligosaccharides reduced SIBO recurrence to just 6.7% over six months. That is a dramatic reduction compared to the 43.7% recurrence seen at nine months with rifaximin alone, though it comes from a single study and needs replication.

Probiotics, Elemental Diets, and Herbal Preparations Offer Credible Alternatives

The review's most practically useful section documents alternatives for patients who do not respond to rifaximin or who want to avoid repeated antibiotic courses. Saccharomyces boulardii CNCM I-745 eliminated SIBO in 80% of decompensated cirrhosis patients, compared to 23% in the placebo group, and also improved hepatic encephalopathy and other complications. Multi-strain probiotic formulations showed positive effects in certain IBS variants as well.

An elemental diet, taken for two weeks, eliminated methane SIBO in 58% of patients, hydrogen SIBO in 100%, and mixed SIBO in 75%, in an uncontrolled study. These numbers are striking, particularly for hydrogen-dominant SIBO, though the lack of a control group means they should be read cautiously. A low-FODMAP diet showed SIBO eradication rates of 50.0% compared to 63.6% for rifaximin in an RCT without a placebo arm, suggesting diet alone is a meaningful intervention rather than a placebo effect.

Herbal preparations achieved similar eradication rates to rifaximin and were effective in some patients who had not responded to the antibiotic. The combination of colimycin and gentamycin eliminated SIBO in approximately 40% of patients with functional bowel diseases. Prucalopride, a prokinetic laxative, showed positive results in a small RCT for constipation-predominant IBS. Fecal microbiota transplantation eliminated SIBO in 71% of chronic intestinal pseudo-obstruction patients in an uncontrolled study, and reduced intestinal hydrogen production in patients with Parkinson's disease.

The Evidence Base Still Rests Heavily on Small, Uncontrolled Studies

The review's authors are direct about the ceiling of current evidence. Most SIBO treatment data come from uncontrolled studies, and most RCTs that do exist enrolled too few participants to draw firm conclusions. Different studies used different breath test substrates, different cut-off values, and different testing protocols, which makes comparing results across trials genuinely difficult. In Crohn's disease, rifaximin achieved 100% eradication in a small RCT versus placebo, but SIBO recurred in all patients within one month, a result that underscores how the underlying disease can overwhelm any treatment.

NIH resources on SIBO note that the actual prevalence of the condition remains largely unknown, which compounds the difficulty of interpreting trial results: without knowing what baseline rates look like in given populations, it is hard to know how much any treatment is truly moving the needle.

What Larger Trials Need to Establish About SIBO Therapy

The review calls for larger placebo-controlled RCTs to verify rifaximin's efficacy and to test the growing list of alternative treatments systematically. Future research priorities include different diets, exercise protocols, prebiotics, postbiotics, new antibiotics, and fecal microbiota transplantation in controlled settings. The exact schedule for retesting SIBO after successful eradication also needs to be defined, since clinicians currently lack consensus on when and how often to recheck.

One candidate already moving through trials is berberine, an affordable compound derived from traditional medicine. A recent RCT found berberine non-inferior to rifaximin for SIBO treatment, which, if replicated, could significantly expand accessible treatment options, particularly in lower-resource settings. For now, rifaximin remains the best-studied option, but the field is moving fast enough that the treatment landscape a few years from now may look quite different from today's.

Evidence rating

EMERGING — 80/100

Caveats:

• This is a narrative review, not a clinical trial — it summarizes existing studies rather than generating new data, and the conclusions are only as strong as the underlying evidence.
• The majority of included studies are uncontrolled, meaning no placebo group, which makes it difficult to separate true treatment effects from spontaneous improvement.
• Most randomized controlled trials in this field are small, and a meta-analysis of rifaximin — the most-studied drug — found no statistically significant effect on SIBO eradication over placebo.
• Breath test protocols varied widely across studies, making direct comparisons unreliable.
• No funding source was disclosed for this review.

Narrative review synthesizing 89 studies and 6 meta-analyses on SIBO treatment across multiple disease contexts. The majority of underlying studies are uncontrolled, and most randomized trials are small and heterogeneous in methodology; a meta-analysis of rifaximin showed no statistically significant eradication benefit over placebo. Results for specific agents such as Saccharomyces boulardii CNCM I-745 in cirrhosis and VSL#3 in IBS are drawn from single small RCTs and have not been independently replicated at scale.

References

1. Roman Maslennikov, Victoria Agarkova, Elena Poluektova, et al. (2026). Treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Gastrointestinal, Hepatic, Endocrine, Neurological, and Postoperative Diseases: A Comprehensive Narrative Review. Medical Sciences. https://doi.org/10.3390/medsci14020300
2. Seong-Eun Kim (2010). Small Intestinal Bacterial Overgrowth. Intestinal Research. https://doi.org/10.5217/ir.2010.8.2.106
3. Satish S. C. Rao, Jigar Bhagatwala (2019). Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clinical and Translational Gastroenterology. https://doi.org/10.14309/ctg.0000000000000078
4. Seong-Eun Kim (2010). Small Intestinal Bacterial Overgrowth. Intestinal Research. https://doi.org/10.5217/ir.2010.8.2.106
5. Jiaqi Gao, Huaizhu Guo, Lingling Zhu, et al. (2025). IDDF2025-ABS-0189 New choice for small intestinal bacterial overgrowth: an RCT comparing berberine and rifaximin. Clinical Gastroenterology. https://doi.org/10.1136/gutjnl-2025-iddf.227